The authors reported that the fucosylated CLU of neoplastic cells, in contrast to the CLU present in healthy cells, has the ability to bind to DC-SIGN, proving that CLU of breast cancer cells contains fucosylated glycans of Lex and/or Ley type, enabling effective binding to DC-SIGN. The gene discussed is CD209; the disease is breast carcinoma.